In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...
In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice President and Chief Science & Technology Officer, sold shares of common ...
Hosted on MSN5d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback